Forwarded from 미래에셋 제약/바이오 김승민
최초의 경구용 마이크로바이옴 치료제 FDA 허가
세레즈의 C. difficile 감염 적응증. 브랜드는
보우스트(Vowst)
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-seres-therapeutics-pill-deadly-c-difficile-infections-2023-04-26/
t.me/bioksm
세레즈의 C. difficile 감염 적응증. 브랜드는
보우스트(Vowst)
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-seres-therapeutics-pill-deadly-c-difficile-infections-2023-04-26/
t.me/bioksm
Reuters
US FDA approves Seres Therapeutics' pill for deadly C. difficile infections
The U.S. health regulator on Wednesday approved Seres Therapeutics Inc's pill for treating a type of bacterial infection, giving an easier and standardized option to patients who often have to rely on individual donors for fecal transplants.